Enabling pseudokinases as potential drug targets.

Baculovirus Inhibitor screening Medium-throughput cloning Pseudokinase X-ray crystallography

Journal

Methods in enzymology
ISSN: 1557-7988
Titre abrégé: Methods Enzymol
Pays: United States
ID NLM: 0212271

Informations de publication

Date de publication:
2022
Historique:
entrez: 7 5 2022
pubmed: 8 5 2022
medline: 11 5 2022
Statut: ppublish

Résumé

Pseudokinases play significant roles in disease development. Similar to active kinases, their cellular functions can be targeted pharmacologically. But notably, instead of inhibiting an enzymatic activity, drug-like molecules act by stabilizing distinct pseudokinase conformations, by interfering with protein interactions, or by inducing proteasomal degradation. Herein, we describe our approach of enabling particular pseudokinases as potential drug targets. The method starts with obtaining recombinant proteins for assay development and for biochemical evaluation. The next step is to probe the pseudoactive site as a binding pocket for small molecules, providing initial insight into binding modes and even candidate chemotypes. Finally, structural features of pseudokinase:inhibitor complexes are explored. Taken together, we provide detailed method descriptions for essential inhibitor development technologies.

Identifiants

pubmed: 35525558
pii: S0076-6879(22)00141-0
doi: 10.1016/bs.mie.2022.03.050
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

663-683

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Auteurs

Franziska Preuss (F)

Structural Genomics Consortium, Buchmann Institute for Molecular Life Sciences, Frankfurt am Main, Germany; Institute for Pharmaceutical Chemistry, Johann Wolfgang Goethe-University, Frankfurt am Main, Germany.

Deep Chatterjee (D)

Structural Genomics Consortium, Buchmann Institute for Molecular Life Sciences, Frankfurt am Main, Germany; Institute for Pharmaceutical Chemistry, Johann Wolfgang Goethe-University, Frankfurt am Main, Germany.

Verena Dederer (V)

Structural Genomics Consortium, Buchmann Institute for Molecular Life Sciences, Frankfurt am Main, Germany; Institute for Pharmaceutical Chemistry, Johann Wolfgang Goethe-University, Frankfurt am Main, Germany.

Stefan Knapp (S)

Structural Genomics Consortium, Buchmann Institute for Molecular Life Sciences, Frankfurt am Main, Germany; Institute for Pharmaceutical Chemistry, Johann Wolfgang Goethe-University, Frankfurt am Main, Germany. Electronic address: knapp@pharmchem.uni-frankfurt.de.

Sebastian Mathea (S)

Structural Genomics Consortium, Buchmann Institute for Molecular Life Sciences, Frankfurt am Main, Germany; Institute for Pharmaceutical Chemistry, Johann Wolfgang Goethe-University, Frankfurt am Main, Germany.

Articles similaires

Investigation of Structural and Spectral Peculiarities of

Anastasia Povolotckaia, Dmitrii Pankin, Vasiliy Novikov et al.
1.00
Fusarium Pigments, Biological Models, Molecular Molecular Conformation Molecular Structure

Harnessing conformational drivers in drug design.

Praful Chovatia, Angelo Sanzone, Gert-Jan Hofman et al.
1.00
Drug Design Molecular Conformation Humans Magnetic Resonance Spectroscopy Pharmaceutical Preparations
Polyelectrolytes Molecular Dynamics Simulation Salts Molecular Conformation Solutions
Anilides Tosyl Compounds Solvents Nitriles Molecular Conformation

Classifications MeSH